Navigation Links
Amarin Announces Completion of the First Tranche of $60 Million Private Placement
Date:5/22/2008

portunities. Dr. Akkaraju holds B.A. degrees in both Biochemistry and Computer Science from Rice University and an M.D. and Ph.D. in Immunology from Stanford University School of Medicine. Dr. Akkaraju currently serves on the board of directors of Presidio Pharmaceuticals, Itero Biopharmaceuticals, Barrier Therapeutics, Inc., Phenomix Corporation, Piramed Limited, Seattle Genetics, Inc., and Pharmos, Inc.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be the sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Amarin

Amarin is a biopharmaceutical company focused on improving the lives of patients suffering from cardiovascular and central nervous system (CNS) diseases. Amarin's cardiovascular programs capitalize on the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin's CNS development pipeline includes programs in myasthenia gravis, Huntington's disease, Parkinson's disease, epilepsy and memory. Amarin also has two proprietary technology platforms: a lipid-based technology platform for the targeted transport of molecules through the liver and/or to the brain, and a unique mRNA technology based on cholinergic neuromodulation. Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital Market ("AMRN").

Disclosure Notice

The information contained in this document is as of May 22, 2008. Amarin assumes no obligation to update any forward-looking statements contained in this document as a result of new information or future events or developments. This document contains forward-looking statements about Amarin's financial condition, results of operations, business prospects and products in research that involve substantial risks and uncertainties. You can identify these statements by the fac
'/>"/>

SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amarin Announces Financial Results for Fourth Quarter and Full Year 2007
2. Amarin Secures Global Intellectual Property Rights for Lipid Programs
3. Amarin Appoints Dr. William Mason as Lead Independent Director
4. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
5. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
6. Amarin Signs Agreement to Acquire Ester Neurosciences
7. Amarin Corporation to Present at Acumen BioFin Rodman & Renshaw Ninth Annual Healthcare Conference
8. Amarin Announces Initiation of Cardiovascular Development Strategy
9. Amarin to Present at 4th Annual Bio Investor Forum
10. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
11. AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... MacroGenics, Inc. announced today that Mr. Paulo F. Costa has ... Mr. Costa is the former President and Chief Executive ... years of experience in operations and commercialization in the pharmaceutical ... , , "We are privileged to have Mr. Costa ...
... VIENNA, Austria, June 23 MIG Fonds and AFFiRiS ... Private Equity Award,competition, hosted by the industry magazine Boerse-Express and ... fund and the Austrian biotechnology company as well as a ... Last Tuesday MIG Fonds and AFFiRiS AG ...
... Denosumab Data , , THOUSAND OAKS, Calif., June 22 ... announced that the U.S. Food and Drug Administration (FDA) has ... Reproductive Health Drugs Advisory Committee (RHDAC) on Aug. 13, 2009. ... (BLA) for denosumab, a RANK Ligand inhibitor for which Amgen ...
Cached Biology Technology:Paulo F. Costa Joins MacroGenics Board of Directors 2Paulo F. Costa Joins MacroGenics Board of Directors 3AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS 2AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS 3Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 2Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 3Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 4Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 5Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 6Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August 7
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/18/2014)...   EyeLock Inc. , a market leader ... USA (Safran), a leading U.S. provider of ... partnership to offer comprehensive biometric identity solutions and ... screening and financial services markets. As ... through a nationwide network of 1,100 IdentoGO® Centers.  ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... could benefit from drinking diet soda. New research from ... citrate and malate content in commonly consumed sodas may ... The study was presented at the 104th Annual Scientific ... Increased alkalinity is proven to augment citraturia, a known ...
... a novel approach for thwarting the relentless bacterial infections ... fibrosis (CF), unlocking new possibilities against a tenacious and ... a mainstay antibiotic with drugs to deprive the bacteria ... boost infection killing, they found. Their research, reported ...
... has a soundtrack. Its tempo and tone will vary, ... the brain itself. When that soundtrack is recorded and ... -- it may sharpen their reflexes during a crisis, and ... influence of music on cognitive development, learning, and emotional well-being ...
Cached Biology News:Two-pronged model could help foil tough cystic fibrosis infections 2Two-pronged model could help foil tough cystic fibrosis infections 3Brain music 2
... is a cytidine analog that has been shown ... Immunogen: Chemical / Small Molecule conjugated ... of the ddC antiserum was determined by calculating ... moles of ddC analog at the 50% intercept ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
...
Biology Products: